Document is current
Any future updates will be listed below
-
Authors
Kanda, Ryuichiro
Miyazaki, Yusuke
Nakayamada, Shingo
Fukuyo, Shunsuke
Kubo, Satoshi
Miyagawa, Ippei
Yamaguchi, Ayako
Satoh-Kanda, Yurie
Ohkubo, Naoaki
Todoroki, Yasuyuki
Tanaka, Hiroaki
Ueno, Masanobu
Nagayasu, Atsushi
Fujita, Yuya
Aritomi, Takafumi
Kusaka, Katsuhide
Sakai, Hidenori
Matsunaga, Satsuki
Nohara, Hirotsugu
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
-
Funding
Funding for this research was provided by:
University of Occupational and Environmental Health, Japan, through the University of Occupational and Environmental Health, Japan, (#19K17919)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 23 January 2025
First Online: 1 March 2025
Declarations
:
: Yusuke Miyazaki has received consulting fees, speaking fees, lecture fees, and/or honorariums from AstraZeneca, GlaxoSmithKline, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Eli Lilly, and Boehringer Ingelheim. Shingo Nakayamada has received consulting fees, speaking fees, lecture fees, and/or honorariums from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, Boehringer Ingelheim and Ayumi. Satoshi Kubo has received speaking fees from Eli Lilly, GlaxoSmithKline, Bristol-Myers, AbbVie, Eisai, Pfizer, AstraZeneca and also research grants from Daiichi-Sankyo, AbbVie, Boehringer Ingelheim, and Astellas. Masanobu Ueno has received speaking fees from GlaxoSmithKline. Yoshiya Tanaka has received speaking fees and/or honorariums from Gilead Sciences, AbbVie, Boehringer Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers, and AstraZeneca; received research grants from Asahi-Kasei, AbbVie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa, and Boehringer Ingelheim; and received consultant fees from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GlaxoSmithKline, and AbbVie. Ryuichiro Kanda, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Yurie Satoh-Kanda, Naoaki Ohkubo, Yasuyuki Todoroki, Hiroaki Tanaka, Atsushi Nagayasu, Yuya Fujita, Takafumi Aritomi, Katsuhide Kusaka, Hidenori Sakai, Satsuki Matsunaga, and Hirotsugu Nohara have nothing to disclose. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: This study was approved by the ethics review board of the University of Occupational and Environmental Health, Japan (approval number #04-23). The FIRST registry includes RA patients who initiated treatment with b/tsDMARDs. Informed consent was obtained from all patients who have consented to the FIRST registry.
